Get the Stockscreener App
0.1632
0.12%
-0.0002
After Hours:
.17
0.0068
+4.17%
Hepion Pharmaceuticals Inc stock is traded at $0.1632, with a volume of 5.13M.
It is down -0.12% in the last 24 hours and down -75.05% over the past month.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
See More
Previous Close:
$0.1634
Open:
$0.165
24h Volume:
5.13M
Relative Volume:
0.33
Market Cap:
$1.73M
Revenue:
-
Net Income/Loss:
$-22.70M
P/E Ratio:
-0.0373
EPS:
-4.38
Net Cash Flow:
$-26.07M
1W Performance:
-12.54%
1M Performance:
-75.05%
6M Performance:
-73.51%
1Y Performance:
-89.67%
1-Day Range:
$0.155
$0.1718
1-Week Range:
$0.149
$0.1858
52-Week Range:
$0.121
$3.4899
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Name
Hepion Pharmaceuticals Inc
Sector
Industry
Phone
732-902-4000
Address
399 THORNALL STREET, EDISON
Compare HEPA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HEPA
Hepion Pharmaceuticals Inc
|
0.1632 | 1.73M | 0 | -22.70M | -26.07M | -4.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-20-20 | Resumed | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc Stock (HEPA) Latest News
An analyst sees good growth prospects for Hepion Pharmaceuticals Inc (HEPA) - SETE News
Hepion Pharmaceuticals Inc (HEPA) Stock: A Year of Decreases and Increases - The InvestChronicle
Understanding HEPA’s financial ratios: A beginner’s guide - US Post News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference - ACCESS Newswire
Hepion Pharmaceuticals launches public offering for proceeds of up to $9M; shares tumble - MSN
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales - Benzinga
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings - Benzinga
Stock market today: Star Fashion Culture Holdings jumped by 680.92% while Hepion Pharmaceuticals saw increase of 147.54% in early trading - Business Upturn
Hepion Pharmaceuticals launches $9 million stock offering - Investing.com India
Hepion Pharmaceuticals announces $9M public offering - TipRanks
Hepion Pharmaceuticals Announces $9.0 Million Public Offering - The Manila Times
Hepion Pharmaceuticals Announces $9M Public Offering with Dual Warrant Structure - StockTitan
Hepion Pharmaceuticals faces potential Nasdaq delisting - Investing.com India
HEPA stock touches 52-week low at $0.43 amid market challenges - Investing.com India
Hepion Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com UK
HEPA stock touches 52-week low at $0.43 amid market challenges By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News Summary - Benzinga
HEPA stock touches 52-week low at $0.46 amid market challenges - Investing.com Canada
Comparing Novo Nordisk A/S (NYSE:NVO) and Hepion Pharmaceuticals (NASDAQ:HEPA) - Defense World
HEPA stock touches 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
HEPAHepion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Hepion Pharmaceuticals Terminates Merger with Pharma Two B - TipRanks
HEPA stock touches 52-week low at $0.49 amid market challenges - Investing.com
Hepion Pharmaceuticals cancels merger and stockholder meeting By Investing.com - Investing.com Canada
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - The Manila Times
Hepion Pharmaceuticals Terminates Strategic Merger with Pharma Two BMajor Deal Cancelled - StockTitan
Oligonucleotide Therapy Market Key Players AnalysisBPCI - openPR
Pharma Two B Announces Poster Presentation on P2B001 at the - GlobeNewswire
Hepion Pharmaceuticals (NASDAQ:HEPA) Shares Down 4.1% – Here’s What Happened - Defense World
Hepion urges shareholder support for Pharma Two B merger - Investing.com India
Hepion urges shareholder support for Pharma Two B merger By Investing.com - Investing.com Canada
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - The Manila Times
Hepion Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals faces Nasdaq delisting risk - Investing.com India
HEPA (Hepion Pharmaceuticals) 3-Year EPS without NRI Growth Rate : 35.30% (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Accounts Receivable : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Long-Term Debt & Capital Leas - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Analysis of ARMISTICE CAPITAL, LLC's Recent Transaction in Hepio - GuruFocus.com
Hepion Pharmaceuticals Inc (CTVRP) Quarterly 10-Q Report - Quartzy
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger - The Manila Times
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce - GlobeNewswire
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67% - MSN
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Will Hepion's AMBITION Be Fulfilled? - RTTNews
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Hepion Pharmaceuticals Inc Stock (HEPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):